Study of a new ALK inhibitor for advanced cancer
Part of Cancer clinical trials.
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is advanced (spread or can't be removed with surgery) and has an ALK gene change.
- You have at least one tumor that can be measured on a scan.
- You are expected to live more than 3 months.
- You are able to do most daily activities (performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AK112 for people with a certain type of advanced lung cancer that has specific gene changes (like EGFR or ALK) and where previous targeted therapy pills stopped working. It is a phase 2 study, so it helps find out if the drug is safe and effective, possibly offering a new option when standard treatments fail.
This trial tests a combination of two targeted therapies (lorlatinib and sacituzumab tirumotecan) as first treatment for advanced non-small cell lung cancer with an ALK gene change. The goal is to see if the combination works better than current treatments and to use a simple blood test to guide therapy.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This study tests a new pill (SY-3505) compared to the standard first treatment (crizotinib) for people with ALK-positive advanced lung cancer that hasn't been treated yet. If you qualify, you'd be randomly assigned to one of these two oral medicines, and the study will see which one works better.
Hear when a new ALK Positive Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.